Clinical Characteristics And Virological Responses To Pegylated Interferon Plus Ribavirin Combination Therapy In The Hepatitis B And C Virus Coinfected Patients
jing you,y z yan,l zhuang,h y chen,xiqi feng,hutcha sriplung,alan geater,virasakdi chongsuvivatwong,y h che,shao jian ma,j h huang,s m yan,r y zhang,s f rao,ben zhong tang
DOI: https://doi.org/10.1016/j.ijid.2014.03.1083
IF: 12.073
2014-01-01
International Journal of Infectious Diseases
Abstract:Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are among the most common causes of advanced chronic liver disease worldwide. HBV/HCV co-infection is not uncommon and the patients with HBV/HCV co-infection have an increased risk of cirrhosis, hepatocellular carcinoma (HCC), and even death. The combination of pegylated interferon (Peg-IFN) plus ribavirin (RBV) is the current standard of care for naïve chronic hepatitis C patients, achieving a high sustained virological response (SVR) rate. The aim of present study is to explore the clinical characteristics of HBV/HCV co-infected patients and the impact of co-infection on the efficacy of Peg-IFN/RBV combination therapy. Methods & Materials: The clinical characteristics of HBV/HCV co-infected patients and the virological responses to Peg-IFN/RBV combination therapy in 89 HBV and HCV co-infected patients were retrospectively analyzed. The primary outcome measurement of antiviral treatment was SVR (seronegative of HCVRNA throughout the 6-month post-treatment follow-up period). Results: Of the 89 HBV/HCV co-infected patients, HCV strains were dominant in 76 patients (85.4%), while HCV and HBV strains were both dominant 13 patients (14.6%). HBV DNA load level and HBeAg positive rate in HBV/HCV co-infected patients was significantly lower than that in HBV mono-infected group (p < 0.01, 0.001, respectively). Serum levels of ALT and AST in co-infected patients were obviously higher than that in mono-infected group (p < 0.001, 0.001, respectively). The SVR rate was significantly lower in the HBV/HCV co-infected patients compared to the HCV mono-infected patients (p < 0.05). However, the significantly lower rate of SVR in the co-infected group was observed among genotype-1 patients (p < 0.05) but not among genotype-2/3 patients (p > 0.05). Partial early virological response (pEVR) rates and virological response at the end of treatment (ETVR) rates were significantly higher in patients co-infected with genotype 1 of HCV and HBV than those in HCV mono-infected patients (p < 0.01, 0.01, respectively). No differences in rapid virological response (RVR), complete early virological response (cEVR), and relapse were observed between co-infected patients with non-genotype 1 of HCV and HBV and mono-infected patients with non-genotype 1 of HCV. Conclusion: Co-infection with HBV and non-genotype 1 of HCV has no impact on virological responses to Peg-IFN/RBV combination therapy.